Abstract

Interstitial lung disease (ILD) is a generic term encompassing over 200 pulmonary disorders that affect the interstitium of the lung to a variable extent concerning inflammatory and fibrotic changes. This pathological remodeling typically results in restrictive lung physiology and abnormalities in exercise, presenting as increasingly severe shortness of breath. Given the variability of ILDs, these diseases create numerous difficulties in management; thus, treatment protocols to stop the progression of the disease and improve patient’s quality of life should be chosen individually. This review aimed to explore the potential benefits of using inhalers in ILD. The keywords “Potential, Benefits, Using, Inhalers, Interstitial Lung Disease, ILD” were used to conduct a thorough literature search in the MEDLINE database to find relevant publications published between 2016 and 2024. Using the proper search terms, Google Scholar was utilized to find and access pertinent scientific publications. Various inclusion criteria were used to choose which articles to select. The research included in this study was published from the years 2016 to 2024. The traditional management of ILD entails the use of systemic therapies to address inflammation and fibrosis simultaneously in a manner that depends on the disease subtype, its severity, and the patient’s characteristics. Further study of the factors involved in the development of ILD is highly needed to help devise specific treatments accordingly. Ultimately, further research and clinical correlation would necessarily refine the practical employment of this marker in PH-ILD.

Key words: Potential benefits, inhalers, interstitial lung disease, ILD, systemic review